<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01700270</url>
  </required_header>
  <id_info>
    <org_study_id>CTKI258A2120</org_study_id>
    <secondary_id>2012-001546-18</secondary_id>
    <nct_id>NCT01700270</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.</brief_title>
  <acronym>CTKI258A2120</acronym>
  <official_title>A Phase I, Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effect of the CYP1A2 Inhibitor, Fluvoxamine, on Dovitinib (TKI258) Pharmacokinetics in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, single-sequence, crossover, drug-drug interaction (DDI)&#xD;
      study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on the PK of dovitinib in&#xD;
      patients with advanced solid tumors, excluding breast cancer. The purpose of this study is to&#xD;
      evaluate the effect of a CYP1A2 inhibitor, 100 mg fluvoxamine, on the PK of dovitinib when&#xD;
      administered at a dose of 300 mg on the dosing schedule, 5 days on/2 days off. The study will&#xD;
      consist of 2 phases: a Pharmacokinetic (PK) phase and a clinical treatment phase. The DDI&#xD;
      test will be conducted in the PK phase. The DDI test will assess the steady state PK profile&#xD;
      of dovitinib when administered alone and in the presence of the CYP1A2 inhibitor, fluvoxamine&#xD;
      (AUC 0-24h, AUC 0-72h and Cmax parameters). During the clinical treatment phase patients may&#xD;
      continue to receive treatment with TKI258 until disease progression (assessed by RECIST 1.1),&#xD;
      unacceptable toxicity, death or discontinuation from the study treatment for any other&#xD;
      reason.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TKI258 pharmacokinetics (PK) parameters: Cmax (Maximum (peak) concentration of drug)</measure>
    <time_frame>multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TKI258 pharmacokinetics (PK) parameters: AUC 0-24 hr (Area Under the Curve)</measure>
    <time_frame>multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TKI258 pharmacokinetics (PK) parameters: AUC 0-72 hr</measure>
    <time_frame>multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TKI258 pharmacokinetics (PK) parameters: Tmax (Time to maximum concentration)</measure>
    <time_frame>multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TKI258 pharmacokinetics (PK) parameters: T1/2 (Half-life time)</measure>
    <time_frame>multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TKI258 pharmacokinetics (PK) parameters: CL/F (Apparent Oral Clearance)</measure>
    <time_frame>multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TKI258 pharmacokinetics (PK) parameters: Vz/F (apparent volume of distribution)</measure>
    <time_frame>multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of AEs (Adverse Events)</measure>
    <time_frame>up to at least 30 days after the last dose of dovitinib (TKI258)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of SAEs (Serious Adverse Events)</measure>
    <time_frame>up to at least 30 days after the last dose of dovitinib (TKI258)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary evidence of antitumor activity of dovitinib (TKI258)</measure>
    <time_frame>every 8 weeks until progression of disease</time_frame>
    <description>overall response based on investigator assessment and best overall response using RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Advanced Solid Tumors, Excluding Breast Cancer</condition>
  <arm_group>
    <arm_group_label>dovitinib (TKI258)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dovitinib, 5 days on / 2 days off dose schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dovitinib (TKI258)</intervention_name>
    <arm_group_label>dovitinib (TKI258)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluvoxamine</intervention_name>
    <description>perpetrator drug; 7 days of dosing</description>
    <arm_group_label>dovitinib (TKI258)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with a cytopathologically or histopathologically confirmed diagnosis of an&#xD;
        advanced solid tumor, excluding breast cancer which has progressed despite standard therapy&#xD;
        or for which no standard therapy exists - ECOG performance status 0 or 1 and an anticipated&#xD;
        life expectancy of â‰¥3 months- Patient must meet protocol-specific laboratory values&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patients with brain metastases - Patients who have received or who are expected to&#xD;
        receive any prohibited medications and therapies - Patients who have received CYP1A2 or&#xD;
        CYP3A inhibitor medications within 5 days prior to start study treatment or are expected to&#xD;
        receive during the first 28 days after starting the study treatment - Patients who have&#xD;
        received CYP1A2 or CYP3A inducer medications within 30 days prior to start study treatment&#xD;
        or are expected to receive during the first 28 days after starting the study treatment -&#xD;
        Patients who are actively taking antidepressants, benzodiazepines, serotonergic drugs,&#xD;
        and/or monoamine oxidase inhibitors (MAOIs) - Patients who have not recovered from previous&#xD;
        anti-cancer therapies - Patient with impairment of gastrointestinal (GI) function or GI&#xD;
        disease that may significantly alter the absorption of TKI258 - Patients who have&#xD;
        concurrent severe and/or uncontrolled concomitant medical conditions that could compromise&#xD;
        participation in the study - Female patients who are pregnant or breast-feeding - Fertile&#xD;
        males or women not willing to use highly effective methods of contraception - Other&#xD;
        protocol-defined inclusion/exclusion criteria will apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center Montefiore Medical Center (SC)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center / UT Health Science Center SC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>GenÃ¨ve</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13925</url>
    <description>Results for CTKI258A2120 on the Novartis Clinical Trial Website</description>
  </link>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>October 2, 2012</study_first_submitted>
  <study_first_submitted_qc>October 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2012</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluvoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

